tiprankstipranks
Merck (NYSE:MRK) Slides after “Guided Missile” Cancer Drug Is Declined
Market News

Merck (NYSE:MRK) Slides after “Guided Missile” Cancer Drug Is Declined

Story Highlights

Merck faces a stock slide as one of its key new drugs fails to get FDA approval.

It was bad news for Merck (NYSE:MRK) today as the drug maker found itself with a dud for a guided missile. A new cancer drug it developed along with Daiichi Sankyo (OTHEROTC:DSKYF) was declined for Food and Drug Administration (FDA) approval. That was bad news enough to send Merck down over 2% in Thursday afternoon’s trading.

Don't Miss our Black Friday Offers:

The drug in question, a lung cancer treatment known as patritumab deruxtecan, is part of a larger family of drugs known as “antibody-drug conjugates” (ADCs). ADCs are described as “guided missiles” among cancer drugs for their ability to specifically target the disease.

As for why the FDA passed on approval, reports noted there were “outstanding questions,” though nothing apparently related to either safety data or efficacy numbers that Merck turned in. So, what exactly is left to complain about is somewhat unclear, but Merck plans to work with the FDA directly to address these “outstanding questions” and get its drug in play in a market that doesn’t have a whole lot of competition right now.

But What About Keytruda?

Merck already had something of a winner in Keytruda, a cancer immunotherapy that produced around $25 billion in sales back in 2023. That was roughly 40% of Merck’s overall revenue. But that also produced an unexpected development. Merck released the results of a Phase 3 study to an online database managed by the federal government…but offered no announcement to the public. This was regarded as unusual, especially given that Merck has previously been fairly brisk in releasing information around Keytruda.

Is Merck Stock a Good Buy?

Turning to Wall Street, analysts have a Strong Buy consensus rating on MRK stock based on 14 Buys and two Holds assigned in the past three months, as indicated by the graphic below. After a 17.36% rally in its share price over the past year, the average MRK price target of $146.45 per share implies 13.84% upside potential.

Disclosure

Related Articles
Samuel O'BrientMerck (MRK) Recommends that Shareholders Reject TRC Capital’s Mini-Tender Offer
TheFlyMerck recommends rejection of TRC Capital’s ‘mini-tender’ offer
TipRanks Auto-Generated NewsdeskMerck & Co. Expands Board with New Director
Go Ad-Free with Our App